CPSE:NOVO BPharmaceuticals
Is Novo Nordisk Attractively Priced After a 22% Drop in 2025?
Ever wondered if Novo Nordisk is a smart buy right now, or if you might be overpaying? You are not alone, especially with all the buzz around its valuation.
In just the last month, Novo Nordisk shares have dropped a steep 22.1%, and are down 58.7% over the past year. This suggests big swings in either growth expectations or risk perception.
Recent headlines highlight changing pharmaceutical regulations and heightened competition in the diabetes and obesity markets. Both factors help explain...